The article presents Atrial fibrillation (AF) to be the most sustained cardiac arrhythmia which leads to cardiac morbidity and mortality. It discusses the agents available for pharmacologic management of AF and states that such agents have a limitation of suboptimal efficacy and proarrhythmic risk. It focuses on the use of rhythm control medical treatment for the patients suffering with paroxysmal and persistent AF.